Your browser is not supported.

To view this content, please use one of the following browsers:

  • Microsoft Edge
  • Chrome
  • Safari

Invokana for DKD – Renal Consequences

Kidney Banner

Prescribing Information

Great Britain Northern Ireland

Burden of DKD

The renal consequences of insufficiently controlled type 2 diabetes mellitus (T2DM)

Kidney Icon

~40% of T2DM patients are affected by diabetic kidney disease (DKD), making it one of the most common complications of T2DM.1

Coin Icone

80% of the cost of managing T2DM is spent managing complications such as DKD and cardiovascular disease (CVD).2

Patient Icon

£26,835 the annual mean NHS England cost of managing one patient on dialysis.3

The link between declining kidney function and mortality

~30% of patients with T2DM have moderately or severely increased albuminuria.4

Kidney disease in type 2 diabetic patients

"Kidney disease predominantly accounts for the increased mortality observed in type 2 diabetes5"


CI: Confidence Interval; CVD: Cardiovascular Disease; DKD: Diabetic Kidney Disease; GFR: Glomerular Filtration Rate; NHS: National Health Service; T2DM: Type 2 Diabetes Mellitus.


  • Diabetic nephropathy – kidney disease. Available at: [Accessed May 2021].
  • Hex N, et al. Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med. 2012;29(7):855-862. doi:10.1111/j.1464-5491.2012.03698.
  • Kerr M. Chronic Kidney Disease in England: The Human and Financial Cost. Available at: [Accessed May 2021].
  • Bramlage P, Lanzinger S, van Mark G, et al. Patient and disease characteristics of type-2 diabetes patients with or without chronic kidney disease: an analysis of the German DPV and DIVE databases. Cardiovasc Diabetol. 2019;18(1):33. Published 2019 Mar 16. doi:10.1186/s12933-019-0837.
  • Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24(2):302-308. doi:10.1681/ASN.2012070718.

Reporting adverse events

Adverse events should be reported. Reporting forms and information can be found at

Adverse events should also be reported to Napp Pharmaceuticals Limited on 01223 424444 or